HEPA
Hepion Pharmaceuticals, Inc. OTC$0.05
Mkt Cap $617,038
52w Low $0.03
4.4% of range
52w High $0.49
50d MA $0.05
200d MA $0.06
P/E (TTM)
-0.1x
EV/EBITDA
0.1x
P/B
0.2x
Debt/Equity
0.0x
ROE
-310.3%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
1.61
50d MA
$0.05
200d MA
$0.06
Avg Volume
16.7K
About
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for th…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2025 | AMC | — | -0.04 | — | 0.07 | +9.0% | +7.5% | +6.0% | +6.0% | +9.0% | +7.5% | — |
| Aug 15, 2025 | AMC | — | -0.09 | — | 0.06 | -15.9% | +3.2% | -9.5% | -17.5% | -7.9% | -12.7% | — |
| May 19, 2025 | AMC | — | -2.15 | — | 0.10 | -3.1% | -16.5% | -20.6% | -16.5% | -20.6% | -26.8% | — |
| Apr 8, 2025 | AMC | -98.50 | -11.12 | +88.7% | 0.41 | +9.8% | +19.0% | +5.1% | +2.9% | -6.1% | -14.6% | — |
| Nov 14, 2024 | AMC | -95.00 | -36.00 | +62.1% | 33.25 | -4.3% | +2.3% | +3.4% | +4.4% | +4.4% | +3.8% | — |
| Aug 13, 2024 | AMC | -185.50 | -34.00 | +81.7% | 29.51 | +1.7% | +11.8% | +14.2% | +10.5% | +18.6% | +26.3% | — |
| Apr 16, 2024 | AMC | -131.50 | -121.00 | +8.0% | 102.00 | +0.5% | +4.4% | +3.5% | -1.5% | -30.9% | -27.0% | — |
| Mar 25, 2024 | AMC | -2.63 | -2.42 | +8.0% | 112.50 | +0.0% | +3.1% | +11.1% | +10.7% | +4.9% | +1.8% | — |
| Nov 20, 2023 | AMC | -134.00 | -137.00 | -2.2% | 157.50 | -2.9% | -1.3% | -5.1% | -0.3% | -5.4% | -1.6% | — |
| Aug 14, 2023 | AMC | -3.32 | -184.00 | -5442.2% | 344.50 | +2.2% | +1.5% | -2.0% | -1.6% | +3.8% | +5.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 7 | Brookline Capital | Downgrade | Buy → Hold | — | $162.00 | $159.00 | -1.9% | -5.6% | +2.2% | +8.6% | +21.9% | +22.8% |
| Feb 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1030.00 | $940.00 | -8.7% | +6.8% | +19.4% | +21.4% | +18.4% | +19.4% |
| Nov 22 | Brookline Capital | Maintains | Buy → Buy | — | $3390.00 | $3390.00 | +0.0% | +5.6% | +5.9% | +36.3% | +85.0% | +106.2% |
| Mar 20 | Maxim Group | Downgrade | Buy → Hold | — | $19250.00 | $18970.00 | -1.5% | -2.9% | -6.7% | -14.5% | -16.0% | -16.2% |
| Jul 10 | Maxim Group | Upgrade | Hold → Buy | — | $82600.00 | $89600.00 | +8.5% | +5.9% | +1.7% | -0.8% | -1.7% | -5.1% |
| May 6 | Maxim Group | Maintains | Buy → Buy | — | $543200.00 | $548800.00 | +1.0% | +2.1% | -5.2% | +2.1% | -2.1% | -9.3% |
Recent Filings
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Hepion Pharmaceuticals executed a material agreement as of April 22, 2026, though specific terms remain undisclosed in this filing excerpt, leaving investors without critical details needed to assess the deal's impact.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Hepta Biosciences' executive leadership change could signal strategic repositioning or internal challenges, warranting investor scrutiny of replacement qualifications and company guidance revisions.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Helios Technologies (HEPA) experienced an executive leadership change that could impact strategic direction, operational execution, and investor confidence depending on the departing executive's role and replacement credentials.
Mar 18
Data updated apr 28, 2026 10:46am
· Source: massive.com